Assessing the reliability of a novel cancer-specific multi-attribute utility instrument (FACT-8D) and comparing its validity to EQ-5D-5L in colorectal cancer patients
- 3 September 2024
- journal article
- research article
- Published by Springer Nature in Quality of Life Research
- Vol. 33 (12) , 3309-3322
Abstract
Objective To examine the test-retest reliability of the Functional Assessment of Cancer Therapy − 8 Dimension (FACT-8D) for the first time, and to conduct a head-to-head comparison of the distribution properties and validity between the FACT-8D and EQ-5D-5L in Colorectal Cancer (CRC) Patients. Methods We conducted a longitudinal study on Chinese CRC patients, employing Functional Assessment of Cancer Therapy-General (FACT-G) and EQ-5D-5L at baseline, and FACT-G during follow-up (2–7 days from baseline). Utility scores for FACT-8D were derived from all available value sets (Australia, Canada and USA), while EQ-5D-5L scores were obtained from corresponding value sets for various countries. We assessed convergent validity using pairwise polychoric correlations between the FACT-8D and EQ-5D-5L; known-groups validity by discriminating participants’ clinical characteristics, and effect size (ES) was tested; test-retest reliability for FACT-8D using kappa and weighted Kappa for choice consistency, and intraclass correlation coefficient (ICC) and Bland-Altman method for utility consistency. Results Among the 287 patients with CRC at baseline, 131 were included in the retest analysis. The utility scores of FACT-8D were highly positively correlated with EQ-5D-5L across various country value sets (r = 0.65–0.77), and most of the dimensions of FACT-8D and EQ-5D-5L were positively correlated. EQ-5D-5L failed to discriminate known-groups in cancer stage across all value sets, whereas both were significant in FACT-8D (ES = 0.35–0.48, ES = 0.38–0.52). FACT-8D showed good test–retest reliability (Cohen’s weighted Kappa = 0.494–0.722, ICC = 0.748–0.786). Conclusion The FACT-8D can be used as a valid and reliable instrument for clinical evaluation of patients with CRC, outperforming EQ-5D-5L in differentiating clinical subgroups and showing promise for cancer practice and research.Keywords
Funding Information
- National Social Science Fund of China (72274045, 71974048)
This publication has 65 references indexed in Scilit:
- The EORTC QLU-C10D is a valid cancer-specific preference-based measure for cost-utility and health technology assessment in the NetherlandsThe European Journal of Health Economics, 2024
- Estimates and Projections of the Global Economic Cost of 29 Cancers in 204 Countries and Territories From 2020 to 2050JAMA Oncology, 2023
- Patient-caregiver agreement and test–retest reliability of the EQ-5D-Y-3L and EQ-5D-Y-5L in paediatric patients with haematological malignanciesThe European Journal of Health Economics, 2021
- Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelinesThe European Journal of Health Economics, 2020
- Condition-specific or generic preference-based measures in oncology? A comparison of the EORTC-8D and the EQ-5D-3LQuality of Life Research, 2016
- QLU-C10D: a health state classification system for a multi-attribute utility measure based on the EORTC QLQ-C30Quality of Life Research, 2016
- Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country studyQuality of Life Research, 2012
- Pharmakoökonomie in der UroonkologieDer Urologe, 2011
- Developing a descriptive system for a new preference-based measure of health-related quality of life for childrenQuality of Life Research, 2009
- Measuring quality of life of Chinese cancer patientsCancer, 2000